Dare Bioscience Inc. recently received an update from Nasdaq regarding its delisting appeal. The Nasdaq Hearings Panel has approved Dare Bioscience's modified plan to comply with the necessary requirements for continued listing. The company must demonstrate compliance by July 31, 2025, and has been granted a conditional continued listing period until August 12, 2025. Failure to meet these requirements could result in the Panel deciding to delist Dare Bioscience's common stock and suspend trading before the August deadline. The company is currently focused on executing its plan and providing necessary updates to Nasdaq to maintain its listing status.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.